A Phase I Study of Matched Unrelated Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Rivogenlecleucel (Primary) ; Rimiducid
- Indications Haematological malignancies; Leukaemia; Lymphoma; Multiple myeloma; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Bellicum Pharmaceuticals
- 05 Dec 2017 Planned initiation date changed from 1 Nov 2017 to 1 Jan 2018.
- 13 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Nov 2017.
- 11 Jul 2017 Planned initiation date changed from 1 May 2016 to 1 Sep 2017.